Article Details

Risk for Progression to Severe COVID-19 Lower With Nirmatrelvir + Ritonavir - Consumer HealthDay

Retrieved on: 2022-03-01 16:53:18

Tags for this article:

Click the tags to see associated articles and topics

Risk for Progression to Severe COVID-19 Lower With Nirmatrelvir + Ritonavir - Consumer HealthDay. View article details on hiswai: https://consumer.healthday.com/lower-risk-of-progression-to-severe-covid-19-with-nirmatrelvir-2656704947.html

Excerpt

... did not receive monoclonal antibodies, efficacy was maintained, with a difference of −5.81 percent (relative risk reduction, 88.9 percent).

Article found on: consumer.healthday.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up